<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>1</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Level and Evaluation of Tumor Marker CA-125 in Ovarian Cancer Patients in Khyber Pakhtunkhwa, Pakistan</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>185</FirstPage>
			<LastPage>189</LastPage>
			<ELocationID EIdType="pii">30411</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Due to the increase in morbidity and mortality rate, cancer has become an alarming threatto the human population worldwide. Since cancer is a progressive disorder, timely diagnosis is necessary toprevent/stop cancer from progressing to a severe stage. In Khyber Paktunkhwa, Pakistan, many tumors arediagnosed with endoscopy and biopsy; rare studies exist regarding the diagnosis and evaluation of ovariancancer, based on tumor markers like CA-125. &lt;br/&gt;&lt;b&gt;Objectives&lt;/b&gt;: The objectives of this study were to investigate andevaluate levels of CA-125 in hospitalized ovarian cancer patients. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: In this study, a totalof 63 admitted patients having ovarian cancer by biopsy were included. The level of CA-125 was determinedin the blood of these patients using ELISA technique. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Out of 63 patients, the level of CA-125 was highin 52% . The affected individuals were more in the group of 40-60 and the level of CA-125 was comparativelyhigher in patients having moderately differentiated histology than those having well differentiated and poorlydifferentiated tumor histology. Moreover, the highest level of CA-125 was present among the patients havingserous subtype of carcinoma and the common stage of carcinoma was stage II followed by stage III, I and IV.&lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: CA-125 level was high in more than 50% of the total patients. Moreover, CA-125 elevation wasmore common in serous subtype and stage II cancer patients.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Ovarian cancer - CA-125 - ELISA - subtypes - Kyber</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Pakistan</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30411_f0461308e1dfdc76a8fde77adaf404bf.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
